Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMANASDAQ:MISTNASDAQ:RZLTNASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$2.26-1.1%$2.09$1.15▼$9.79$349.80M1.893.79 million shs2.09 million shsMISTMilestone Pharmaceuticals$1.90+0.8%$1.52$0.63▼$2.75$101.31M0.95947,177 shs305,403 shsRZLTRezolute$4.79+8.4%$4.03$2.22▼$6.19$412.04M1.03640,565 shs645,210 shsUPXIUpexi$3.01+4.0%$10.21$1.90▼$22.57$114.29M-0.571.53 million shs1.80 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte+9.09%+2.24%-14.93%+56.16%-57.54%MISTMilestone Pharmaceuticals-3.09%+5.03%+15.69%+134.09%+40.30%RZLTRezolute-0.90%+4.25%+8.07%+46.36%+2.55%UPXIUpexi-3.02%-27.20%-71.01%+31.36%-61.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHUMAHumacyte2.6666 of 5 stars3.53.00.00.01.32.50.6MISTMilestone Pharmaceuticals2.8218 of 5 stars3.25.00.00.02.02.50.0RZLTRezolute3.1209 of 5 stars3.61.00.00.04.24.20.0UPXIUpexi3.2731 of 5 stars3.53.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 3.00Buy$11.71419.48% UpsideMISTMilestone Pharmaceuticals 2.40Hold$7.00269.39% UpsideRZLTRezolute 3.14Buy$11.83147.04% UpsideUPXIUpexi 3.00Buy$16.00432.45% UpsideCurrent Analyst Ratings BreakdownLatest MIST, HUMA, RZLT, and UPXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$1.57M222.80N/AN/A($0.41) per share-5.50MISTMilestone Pharmaceuticals$1M101.31N/AN/A$0.25 per share7.58RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/AUPXIUpexi$26M4.38N/AN/A$6.24 per share0.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)MISTMilestone Pharmaceuticals-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%7/8/2025 (Estimated)Latest MIST, HUMA, RZLT, and UPXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyte0.363.683.28MISTMilestone Pharmaceuticals4.064.674.67RZLTRezoluteN/A8.438.43UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%MISTMilestone Pharmaceuticals86.18%RZLTRezolute82.97%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipHUMAHumacyte5.10%MISTMilestone Pharmaceuticals19.50%RZLTRezolute18.39%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150155.12 million147.21 millionOptionableMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableUPXIUpexi13037.92 million25.93 millionOptionableMIST, HUMA, RZLT, and UPXI HeadlinesRecent News About These CompaniesUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell | MorningstarJune 27, 2025 | morningstar.comMUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform - NasdaqJune 27, 2025 | nasdaq.comSolana-Focused Upexi to Tokenize Shares; Added 56K SOL to HoldingsJune 26, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening BellJune 26, 2025 | theglobeandmail.comUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell PlatformJune 26, 2025 | quiverquant.comQUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening BellJune 26, 2025 | globenewswire.comSolana Treasury Firm Upexi Falls After Insider Sales FilingJune 25, 2025 | bloomberg.comNews Explorer — Crypto Treasury Chaos: Why Ethereum's SBET and Solana's UPXI Plunged After Routine SEC FilingsJune 25, 2025 | decrypt.coDUpexi stock plunges after filing allows investors to sell sharesJune 24, 2025 | in.investing.comUpexi’s Solana treasury backfires with 60%+ dip as 43 million shares hit open marketJune 24, 2025 | msn.comSOL Drops Below $150 After Sell-Off Despite Growing Institutional Adoption NarrativeJune 17, 2025 | coindesk.comUpexi, Inc. CSO Brian Rudick to Speak at ICR Conference on Public Market Crypto StrategiesJune 17, 2025 | quiverquant.comQUpexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20thJune 17, 2025 | globenewswire.comUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestJune 17, 2025 | marketbeat.comCantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to "Overweight"June 16, 2025 | marketbeat.comUpexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ETJune 14, 2025 | seekingalpha.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?June 11, 2025 | marketbeat.comUpexi, Inc. Joins Webull Corporate Connect Service to Enhance Investor Engagement and CommunicationJune 11, 2025 | nasdaq.comHODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable ReportJune 10, 2025 | finance.yahoo.comHODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable ReportJune 10, 2025 | finance.yahoo.comUpexi Joins Webull Corporate Connect Service PlatformJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIST, HUMA, RZLT, and UPXI Company DescriptionsHumacyte NASDAQ:HUMA$2.26 -0.03 (-1.10%) As of 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Milestone Pharmaceuticals NASDAQ:MIST$1.90 +0.02 (+0.80%) As of 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Rezolute NASDAQ:RZLT$4.79 +0.37 (+8.37%) As of 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Upexi NASDAQ:UPXI$3.00 +0.12 (+3.98%) As of 03:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
